Brokerages Set DexCom, Inc. (NASDAQ:DXCM) Price Target at $141.67

DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $141.67.

Several equities analysts have issued reports on DXCM shares. UBS Group upped their price objective on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Canaccord Genuity Group raised their price target on DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. Citigroup boosted their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Raymond James increased their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday, April 26th. Finally, Royal Bank of Canada started coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 629 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $126.25, for a total value of $79,411.25. Following the completion of the transaction, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Michael Jon Brown sold 629 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $126.25, for a total transaction of $79,411.25. Following the transaction, the executive vice president now owns 68,212 shares of the company’s stock, valued at approximately $8,611,765. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 190,004 shares of company stock valued at $25,610,270. 0.41% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently modified their holdings of the stock. DSM Capital Partners LLC purchased a new position in DexCom in the fourth quarter valued at approximately $28,000. Riverview Trust Co acquired a new stake in DexCom in the 1st quarter valued at $32,000. Valley National Advisers Inc. raised its position in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. MV Capital Management Inc. lifted its stake in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Finally, Smithfield Trust Co boosted its position in shares of DexCom by 103.1% in the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock worth $40,000 after buying an additional 165 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Up 1.4 %

Shares of NASDAQ DXCM opened at $128.37 on Friday. The business has a 50-day moving average of $132.11 and a two-hundred day moving average of $120.49. The company has a market capitalization of $51.05 billion, a price-to-earnings ratio of 82.82, a price-to-earnings-growth ratio of 2.19 and a beta of 1.23. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. On average, analysts forecast that DexCom will post 1.78 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.